Drug Type Prophylactic vaccine, Genetically engineered subunit vaccine |
Synonyms Hepatitis E vaccine recombinant |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis | Phase 2 | Nepal | 09 Jul 2001 | |
Hepatitis E | Phase 2 | - | - | |
Hepatitis E | Phase 2 | - | - | |
Hepatitis E | Phase 2 | - | - | |
Hepatitis E | Phase 2 | - | - |
Phase 2 | 2,000 | (20mcg Recombinant HEV) | yvlxgwdztz(qjmnelynfx) = hpjmrdnvsw rkcnowymye (vrbpzxjtbn, zmibkfmvwc - ickvykwrzs) View more | - | 29 May 2019 | ||
Placebo (Placebo) | yvlxgwdztz(qjmnelynfx) = gemrkfssiw rkcnowymye (vrbpzxjtbn, mbpuiqkhki - gqvtmvdndi) View more |